Compare PDX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | ELVN |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.5M | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | PDX | ELVN |
|---|---|---|
| Price | $21.59 | $19.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $41.20 |
| AVG Volume (30 Days) | N/A | ★ 641.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.52 | $13.30 |
| 52 Week High | $21.05 | $25.96 |
| Indicator | PDX | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 43.57 |
| Support Level | $21.11 | $21.05 |
| Resistance Level | $21.98 | $22.14 |
| Average True Range (ATR) | 0.38 | 1.38 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 58.10 | 27.72 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.